Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humira in moderate to severe chronic plaque psoriasis (REVEAL)
NCT00237887Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Dec 2004
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Humira with Placebo (2 arms). Primary endpoint: Psoriasis Area and Severity Index 75% improvement at 16 weeks. Started Dec 2004; status: completed.
02
Drugs
Trudexa
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00237887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237887.